Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- AJMC Approves Draft of COI Management Guidelines
November 20, 2013
- JAMS COI Panel to Nudge JPMA to Create Funding Database
November 19, 2013
- JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
- Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
- Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
- JSH2014 GL for Management of Hypertension to Emphasize Transparency, Remove References to Discredited Papers
October 29, 2013
- Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
- Skills for Clinical Studies Required to Become Authorized Hypertension Specialist: JSH
October 28, 2013
- Kyoto Heart Study Chief Investigator to Leave JSH; JSH Ethics Committee Will Continue Investigation
October 28, 2013
- Japan’s First Guidelines for Hematological Malignancy Treatment Compiled by Japanese Society of Hematology
October 24, 2013
- President of Kyoto Prefectural University of Medicine Reprimanded Over Diovan Scandal, Diovan Study Chief Investigator Returns Retirement Allowance
October 17, 2013
- Shiga University of Medical Science to Unveil Diovan Probe Results at Month-End
October 16, 2013
- University of Tokyo Professor Says Results of Diovan Investigations Need to Be Made Open Globally
October 1, 2013
- National University Hospital Council Urges Immediate Check-Up on Hospital’s Clinical Research Systems
September 25, 2013
- AJMC to Unify COI Management Guidelines, Release Draft in December
September 24, 2013
- Use Double-Blind Method to Regain Confidence in Japanese Clinical Trials: Dr Yui of Kyoto Univ. Hospital
September 10, 2013
- The Lancet Announces Retraction of JIKEI Paper on Diovan Trial, Says There’s “Sufficient Doubt”
September 9, 2013
- Tokushukai Group to Cancel Use of Diovan Products at Its 66 Hospitals
August 28, 2013
- Go-Between Faculty Member for Ex-Employee and Osaka City University Received 4 Million Yen in Grants from Novartis
August 26, 2013
- Osaka City University Slams Lead Investigators of Diovan Trials; They “Knew of His Novartis Affiliation”
August 26, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…